ASH 2011 Conference Coverage

Companion diagnostic test improves detection of BRCA mutations in patients with ovarian cancer

The Tumor BRACAnalysis CDx companion diagnostic test boosted the detection of cancer-causing BRCA1/2 mutations in women with ovarian cancer by over 40 percent.

Landmark Medicare law had little impact on reducing chemotherapy cost

Legislation passed in 2003 intended to slow the spiraling costs of drugs paid for by the federal government to treat Medicare patients has not proved to be a success.

Early palliative care reduces hospital readmissions by 23% for patients with cancer

Researchers designed a collaborative approach in cancer care that decreased the number of patients readmitted.

For nonadherent patients, individualized testing does not increase colorectal cancer screening rates

Patients who know individual risk for colorectal cancer are not sufficient to convince previously nonadherent patients.

70-Gene signature not likely to be cost-effective for breast cancer

Findings in comparative economic analysis of patients with node-negative breast cancer showed the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making.

Follow-up colonoscopies too frequent and overused by endoscopists

A retrospective study has uncovered an overuse of colonoscopies for colorectal cancer screening and surveillance.

Current therapy for hypothyroidism endorsed by new guidelines

A recent review has found insufficient consistent data exist to recommend a change in use of levothyroxine as the only drug needed to treat hypothyroidism.

Breast cancer is more accurately diagnosed after PET/CT imaging in younger patients

A change in diagnosis resulted from PET/CT imaging of patients who were younger than 40 years with an initial diagnosis of stage I-III breast cancer, according to a retrospective analysis.

For patients with low-risk prostate cancer managed with active surveillance, obesity may increase risk of progression

Obesity is linked with increased risk of progression of low-risk prostate cancers in active surveillance.

Smoking increases risk of second primary lung cancer (SPLC)

Increased tobacco exposure is linked with a higher risk of developing second primary lung cancers (SPLCs).

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs